Endologix Inc (ELGX) Quote

ELGXQ: Bankruptcy PLAN effective. All shares cancelled.

https://otce.finra.org/otce/dailyList?viewType=Deletions

Looking sexy

Curious...

https://www.renaissancecapital.com/Profile/DFHTU/Deerfield-HealthTech-Acq/IPO

So ELGX files for chapter 11 to restructure and eventually become a private company, while DFHTU is about to IPO? Interesting....

https://deerfield.com

https://sec.report/Document/0001104659-20-083807/

Not sure what all this means for ELGX common shareholders, but it sure does pique my interest. I’ll keep digging...

Endologix Enters into an Agreement with Deerfield Partners to Take the Company Private

https://www.businesswire.com/news/home/20200705005040/en/%C2%A0endologix-enters-agreement-deerfield-partners-company-private

ELGX changed to ELGXQ, bankruptcy. Delisted from the Nasdaq to the OTC:

https://otce.finra.org/otce/dailyList?viewType=Additions

* * $ELGX Video Chart 07-14-2020 * *

Link to Video - click here to watch the technical chart video

Pete whata good? U in?

$ELGX Endologix Inc. (NASDAQ:ELGX) is Gaining Momentum on Earnings Catalyst

https://oracledispatch.com/2020/07/07/endologix-inc-nasdaqelgx-is-gaining-momentum-on-earnings-catalyst/

ELGX WSJ NEWS " Endologix Wins Court Approval to Tap Deerfield Bankruptcy Loan
Medical-device maker clears initial court hurdle and can move forward with sale to health care-focused investment firm Deerfield Management
By Patrick Fitzgerald
July 7, 2020 3:15 pm ET "

https://www.wsj.com/articles/endologix-wins-court-approval-to-tap-deerfield-bankruptcy-loan-11594149313


$ELGX

* * $ELGX Video Chart 07-07-2020 * *

Link to Video - click here to watch the technical chart video

voluntary Chapter 11 July 5, 2020, Endologix, Inc. https://www.sec.gov/ix?doc=/Archives/edgar/data/1013606/000101360620000117/form8-kbankruptcy.htm

In July, 2020 the (ELGX) Endologix, Inc. SqueezeTrigger Price was $0.27. If you had purchased ELGX, the trade would have gained -4.20% as of today's price of $0.26.(((((Here we GO!!)))

And such a great board it was!!!!!

LoL, is it gunna bounce....?????

file for bk chapter 11

* * * $ELGX EM Band Chart Analysis * * *

Could be a good entry point. But that caution indicator. Maybe a gamble play.

VOLUME SPIKE THIS AM.. SOMETHING COOKING

I AM IN

* * $ELGX Video Chart 02-25-2020 * *

Link to Video - click here to watch the technical chart video

M&M's cleaned the floor, picked up some more shares to sell. Going back up now.

Institutions hold over 80% of this company. Only 70% just a few days ago. Someone is buying.

* * $ELGX Video Chart 02-24-2020 * *

Link to Video - click here to watch the technical chart video

ELGX lighting up.....

Five years down 97%.

R/S to be 1-10 at Open

https://www.streetinsider.com/Press+Releases/Endologix+Announces+Approval+of+Reverse+Stock+Split/15219992.html

IRVINE, Calif.--(BUSINESS WIRE)-- Endologix, Inc. (the “Company”) (NASDAQ: ELGX) previously announced that a proposal was approved at its Special Meeting of Stockholders, held February 22, 2019, authorizing its Board of Directors to amend the Company's certificate of incorporation to effect a reverse stock split of the Company’s issued and outstanding shares of common stock at a ratio not less than 1-for-5 and not greater than 1-for-10 (inclusive), with the exact ratio to be set within that range by the Company’s Board of Directors. The number of authorized shares of common stock would remain at 170 million shares, and the number of authorized shares of preferred stock would remain at 5 million shares.?The Company’s Board of Directors had previously directed that the proposal be submitted to the stockholders for approval and has subsequently approved the reverse stock split at a ratio of 1-for-10. The reverse stock split will take effect at 4:00 p.m. ET on March 5, 2019. Beginning with the opening of trading on March 6, 2019, the Company's common stock will trade on the NASDAQ Global Select Market on a reverse stock split-adjusted basis.

Upon the effectiveness of the reverse stock split, every ten shares of the Company's issued and outstanding common stock will be automatically reclassified and converted into one issued and outstanding share of common stock, par value $0.001 per share. As a result of the reverse split, there will be approximately 10.3 million shares of common stock issued and outstanding. The shares of common stock will trade under a new CUSIP number, 29266S304, effective March 6, 2019.?The Company’s trading symbol will remain “ELGX.” All options, warrants, and convertible securities of the Company outstanding immediately prior to the reverse stock split will be adjusted.

No fractional shares of common stock will be issued as a result of the reverse stock split. Stockholders who would otherwise be entitled to receive a fractional share as a result of the reverse stock split will instead receive one whole share of common stock.

The Company has chosen its transfer agent, American Stock Transfer & Trust Company, LLC (“AST”), to act as exchange agent for the reverse stock split.?Stockholders owning shares via a bank, broker or other nominee will have their positions automatically adjusted to reflect the reverse stock split, and will not be required to take further action in connection with the reverse stock split, subject to brokers' particular processes.?For those stockholders holding physical stock certificates, AST will send instructions for exchanging those certificates for shares held in book-entry form representing the post-split number of shares. AST can be reached at (800) 937-5449.

About Endologix, Inc.

The Company develops and manufactures minimally invasive treatments for aortic disorders. The Company's focus is in endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once an AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 80%, making it a leading cause of death in the U.S. For more information, visit www.endologix.com.

The Nellix® EndoVascular Aneurysm Sealing System and Ovation Alto® Abdominal Stent Graft System, the Company's next generation Ovation system device, are approved only as investigational devices and are not currently approved for commercial purposes in any market.

ELGX Time to wake up. It rumbles https://stockcharts.com/public/1164099

This puppy taking its time. This dog better go soon or I’m out.

News: $ELGX Endologix Provides Update on Previously Announced Voluntary Nellix System Recall

Endologix® Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, announced today that the EC Certificate of Conformity (CE Mark) for the Nellix EndoVascular Aneurysm Sealing System (Nellix System) has been suspended by its Notified Body, GMED, foll...

In case you are interested https://marketwirenews.com/news-releases/endologix-provides-update-on-previously-announced-voluntary-nellix-system-recall-7447556.html

MBD

In today at .85

N huge reversal coming! MBD

Weekly chart looks awesome. I’m in if it’s green tomorrow.

* * $ELGX Video Chart 02-15-18 * *

Link to Video - click here to watch the technical chart video

Partner Fund Management, L.P. has filed a new 13G, reporting 6.4% ownership in $ELGX - https://fintel.io/so/us/elgx and https://fintel.io/i/partner-fund-management

Analyst On Endologix: No Sense In Downgrading Now

https://www.benzinga.com/analyst-ratings/analyst-color/17/05/9486445/analyst-on-endologix-no-sense-in-downgrading-now

ELGX

Endologix, Inc. (NASDAQ:ELGX) Updates Physicians Concerning Stent Graft Treatment Devices http://marketexclusive.com/endologix-updates-physicians-concerning-stent-graft-treatment-devices/57218/?icd1

ELGX bearish 6.25

gap down
went through major support






normal chart




log chart

Picked some up today in around mid 9 looks over sold here.

Only the beginning. Again. Much more in stock here to come. Could see $16 in no time IMO. Chart says it all. Glta

8:18 AM Endologix (ELGX) reports preliminary unaudited sales for Q2 of ~$34M (+33% Y/Y) and raises FY13 revenue guidance to $128-134M. The company now projects a wider net loss than previously expected however and also says it is temporarily suspending enrollment in its Ventana U.S. IDE clinical trial.

Endologix Reports 22% Revenue Growth for the First Quarter 2013

Provides Update on New Product Pipeline Including Enhancements to Ventana Program That Will Delay IDE Enrollment and Limited Market Introduction in Europe

Reiterates 2013 Financial Guidance


Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, today announced financial results for the three months ended March 31, 2013 and provided an update on the company's new product pipeline.

John McDermott, Endologix President and Chief Executive Officer, said, "We are very pleased with our sales growth in the U.S. and international markets in the first quarter 2013, driven by continued adoption of the AFX® Endovascular AAA System. In Europe, we began the limited market introduction of the Nellix® EndoVascular Aneurysm Sealing System and have received very positive physician feedback on its ease-of-use and clinical outcomes from these first commercial procedures. In addition, we recently received FDA approval for our percutaneous EVAR (PEVAR) indication with AFX and have physician training courses scheduled to begin in May. After our first 120 procedures with the Ventana™ Fenestrated System, we have seen good overall safety results, but a higher than expected number of renal re-interventions. Before we continue enrolling patients in the IDE clinical study and begin the EU limited introduction, we plan to integrate our next generation covered renal stent and conduct additional testing and training to optimize future outcomes. We hope to begin enrolling patients in the study again and start the limited market introduction in Europe by the end of this year."

Mr. McDermott concluded, "Despite the temporary delay in the Ventana program, we are reiterating our guidance for the year based on the strong performance trends in our core business. We continue to believe Ventana represents a significant new innovation in the treatment of juxta and para-renal aortic aneurysms, with the potential to expand the addressable EVAR market. In addition, the limited market introduction of Nellix is going extremely well and we hope to begin enrolling patients in the U.S. IDE by the end of this year".

Financial Results

Global revenue in the first quarter of 2013 was $29.8 million, a 22% increase from $24.5 million in the first quarter of 2012. U.S. revenue in the first quarter of 2013 was $24.7 million, a 17% increase compared with $21.1 million in the first quarter of 2012, which was largely driven by the continued adoption of the AFX system and the expansion of the U.S. sales force through the addition of sales representatives and clinical specialists that exclusively provide field support to our sales representatives, increasing overall sales force productivity. International revenue was $5.1 million, a 46% increase compared to $3.5 million in the first quarter of 2012. The international sales increase is primarily attributable to a transition to a direct sales organization in Europe, beginning in September 2011.

Gross profit was $22.5 million in the first quarter of 2013, which represents a gross margin of 76%. This compares with gross margin of 78% in the first quarter of 2012. Lower gross margins are primarily the result of product mix and the greater proportion of our global sales from international customers, as opposed to U.S. customers.

Total operating expenses were $27.0 million in the first quarter of 2013, compared to $22.8 million in the first quarter of 2012.

Marketing and sales expenses were $15.2 million in the first quarter of 2013, an increase from $13.5 million in the prior year period. The increase was driven by the costs associated with our direct sales expansion in Europe, and the increase in variable compensation expense associated with our revenue increase.

Research and development expenses were $3.5 million in the first quarter of 2013, substantially similar to the prior year period. Research and development expenses in the first quarter of 2013 were primarily related to the continued development of our Nellix and Ventana systems and enhancements to the AFX system.

Clinical and regulatory affairs expenses were $2.4 million in the first quarter of 2013, an increase from $1.4 million in the prior year period. The increase was primarily driven by the continued enrollment in the Ventana U.S. clinical trial, follow-up costs associated with Ventana and Nellix studies, and regulatory costs for CE and FDA submissions.

General and administrative expenses were $5.9 million in the first quarter of 2013, up from $4.1 million in the prior year period. The increase was driven primarily by the Company's expanding European operations, the new federal Medical Device Excise Tax, and legal and consulting expenses associated with general business growth.

Endologix reported a net loss for the first quarter of 2013 of $9.3 million, or $(0.15) per share, compared with a net loss of $16.7 million, or $(0.29) per share, for the first quarter of 2012. The first quarter 2013 loss includes a $5.2 million non-cash charge, or $(0.08) per share, for the increase of the contingent consideration (solely payable in the form of our common stock) related to the Nellix acquisition. Endologix reported Adjusted Net Loss (non-GAAP and defined below) for the first quarter of 2013 of $4.1 million, or $(0.07) per share, compared with an Adjusted Net Loss (non-GAAP and defined below) for the first quarter of 2012 of $4.3 million, or $(0.07) per share.

Total cash and cash equivalents were $42.0 million as of March 31, 2013, compared to $45.1 million as of December 31, 2012.

Financial Guidance

Based on the first quarter 2013 results and recent developments, Endologix is reiterating its full year 2013 financial guidance. Endologix anticipates 2013 revenue to be in the range of $126 million to $133 million, representing growth of 19% to 25% from 2012. Endologix anticipates a GAAP loss in 2013 of $(0.14) to $(0.17) per share, excluding the effect of increases or decreases in the Nellix contingent consideration and an Adjusted EBITDA (non-GAAP and defined below) of $0.01 to $0.05 per share. Endologix anticipates generating positive cash flows from operations in the second half of 2013.

Conference Call Information

Endologix's management will host a conference call today to discuss these topics, beginning at 5:00 P.M. Eastern time (2:00 P.M. Pacific time). To participate via telephone please call (877) 407-0789 from the U.S. or 1-201-689-8562 from outside the U.S. A telephone replay will be available for seven days following the completion of the call by dialing (877) 870-5176 from the U.S. or 1-(858)-384-5517 from outside the U.S., and entering pin number 412281. The conference call will be broadcast live over the Internet at www.endologix.com and will be available for 30 days. After the live webcast, a webcast replay of the call and a transcript of the call will be available online from the investor relations page of Endologix's website for 30 days.http://seekingalpha.com/news-article/6396241-endologix-reports-22-revenue-growth-for-the-first-quarter-2013

http://seekingalpha.com/article/1231921-endologix-s-ceo-discusses-q4-2012-results-earnings-call-transcript

5:07 PM Endologix (ELGX): Q4 EPS of -$0.09 misses by $0.06. Revenue of $29.2M (+25% Y/Y) beats by $0.17M

8:33AM Endologix announces presentation of data From PEVAR randomized trial; 94% procedural technical success rate; 'significantly' reduced procedure times and time to hemostasis (ELGX) 15.63 : Co announced that data from the first prospective, multicenter, randomized clinical trial of a totally percutaneous approach (PEVAR) to endovascular abdominal aortic aneurysm repair (EVAR) was recently presented at two medical meetings. Key points from the trial include:

The primary trial endpoint was met (P<.0036), definitively demonstrating the non-inferiority of PEVAR using the ProGlide closure device to surgical EVAR
A 94% procedural technical success rate was achieved in a multicenter setting
Mean procedure time was reduced in PEVAR patients by 34 minutes (P=.006). Likewise, mean time to hemostasis was reduced following PEVAR by 13 minutes (P=.002)
PEVAR patients required significantly fewer concomitant procedures
Favorable trending of PEVAR in several clinical utility outcomes including reduced anesthesia time, reduced blood loss and need for transfusion, shorter hospital length of stay, and less analgesics prescribed for groin pain
The PEVAR non-inferiority to surgical EVAR persisted through the final 6-month follow-up

Another 52 week high today!

New 52 Week High at 14.90
Let's see if it closes there or above

<<< $ELGX Links! >>> ~ MAC's Quick DD Links without the charts.




PennyStockTweets ~ http://www.pennystocktweets.com/stocks/profile/ELGX


OTC Markets Company Info ~ http://www.otcmarkets.com/stock/ELGX/company-info
OTC Markets Charts ~ http://www.otcmarkets.com/stock/ELGX/chart
OTC Markets Quote ~ http://www.otcmarkets.com/stock/ELGX/quote
OTC Markets News ~ http://www.otcmarkets.com/stock/ELGX/news
OTC Markets Financials ~ http://www.otcmarkets.com/stock/ELGX/financials
OTC Markets Short Sales ~ http://www.otcmarkets.com/stock/ELGX/short-sales
OTC Markets Insider Disclosure ~ http://www.otcmarkets.com/stock/ELGX/insider-transactions
OTC Markets Research Reports ~ http://www.otcmarkets.com/stock/ELGX/research


Google Finance Summary ~ http://www.google.com/finance?q=ELGX
Google Finance News ~ http://www.google.com/finance/company_news?q=ELGX
Google Finance Option chain ~ http://www.google.com/finance/option_chain?q=ELGX
Google Finance Financials ~ http://www.google.com/finance?q=ELGX&fstype=ii#
Google Finance Historical prices Daily ~ http://www.google.com/finance/historical?q=ELGX
Google Finance Historical prices Weekly ~ http://www.google.com/finance/historical?q=ELGX&histperiod=weekly#


Y! < Company >
Y! Profile ~ http://finance.yahoo.com/q/pr?s=ELGX+Profile
Y! Key Stat's ~ http://finance.yahoo.com/q/ks?s=ELGX+Key+Statistics
Y! Headlines ~ http://finance.yahoo.com/q/h?s=ELGX+Headlines
Y! Summary ~ http://finance.yahoo.com/q?s=ELGX
Y! Historical Prices ~ http://finance.yahoo.com/q/hp?s=ELGX+Historical+Prices
Y! Order Book ~ http://finance.yahoo.com/q/ecn?s=ELGX+Order+Book
Y! Message Boards ~ http://messages.finance.yahoo.com/mb/ELGX
Y! Market Pulse ~ http://finance.yahoo.com/marketpulse/ELGX
Y! Technical Analysis ~ http://finance.yahoo.com/q/ta?s=ELGX+Basic+Tech.+Analysis
Y! < Analyst Coverage >
Y! Analyst Opinion ~ http://finance.yahoo.com/q/ao?s=ELGX+Analyst+Opinion
Y! Analyst Estimates ~ http://finance.yahoo.com/q/ae?s=ELGX+Analyst+Estimates
Y! Research Reports ~ http://finance.yahoo.com/q/rr?s=ELGX+Research+Reports
Y! Star Analysts ~ http://finance.yahoo.com/q/sa?s=ELGX+Star+Analysts
Y! < Ownership >
Y! Major Holders ~ http://finance.yahoo.com/q/mh?s=ELGX+Major+Holders
Y! Insider Transactions ~ http://finance.yahoo.com/q/it?s=ELGX+Insider+Transactions
Y! Insider Roster ~ http://finance.yahoo.com/q/ir?s=ELGX+Insider+Roster
Y! < Financials >
Y! Income Statement ~ http://finance.yahoo.com/q/is?s=ELGX+Income+Statement&annual
Y! Balance Sheet ~ http://finance.yahoo.com/q/bs?s=ELGX+Balance+Sheet&annual
Y! Cash Flow ~ http://finance.yahoo.com/q/cf?s=ELGX+Cash+Flow&annual


FINVIZ ~ http://finviz.com/quote.ashx?t=ELGX&ty=c&ta=0&p=d


Investorshub Trades ~ http://ih.advfn.com/p.php?pid=trades&symbol=ELGX
Investorshub Board Search ~ http://investorshub.advfn.com/boards/getboards.aspx?searchstr=ELGX
Investorshub PostStream ~ http://investorshub.advfn.com/boards/poststream.aspx?ticker=ELGX
Investorshub Messages ~ http://investorshub.advfn.com/boards/msgsearch.aspx?SearchStr=ELGX
Investorshub Videos ~ http://ih.advfn.com/p.php?pid=ihvse&ihvqu=ELGX
Investorshub News ~ http://ih.advfn.com/p.php?pid=news&btn=s_ok&ctl00%24sb3%24tbq1=Get+Quote&as_values_IH=&ctl00%24sb3%24stb1=Search+iHub&symbol=ELGX&s_ok=OK&from_month=3&from_day=15&from_year=2012&order=desc&selsrc%5B%5D=prnca&selsrc%5B%5D=prnus&selsrc%5B%5D=zacks&selsrc%5B%5D=money2&selsrc%5B%5D=djn&selsrc%5B%5D=bw&selsrc%5B%5D=globe&selsrc%5B%5D=edgar&selsrc%5B%5D=mwus&force=1&last_ts=1331855999&p_n=1&p_count=&p_ts=1331794260


CandlestickChart ~ http://www.candlestickchart.com/cgi/chart.cgi?symbol=ELGX&exchange=US


Barchart Quote ~ http://barchart.com/quotes/stocks/ELGX?
Barchart Detailed Quote ~ http://barchart.com/detailedquote/stocks/ELGX
Barchart Options Quotes ~ http://barchart.com/options/stocks/ELGX
Barchart Technical Chart ~ http://barchart.com/charts/stocks/ELGX&style=technical
Barchart Interactive Chart ~ http://barchart.com/charts/stocks/ELGX&style=interactive
Barchart Technical Analysis ~ http://barchart.com/technicals/stocks/ELGX
Barchart Trader's Cheat Sheet ~ http://barchart.com/cheatsheet.php?sym=ELGX
Barchart Barchart Opinion ~ http://barchart.com/opinions/stocks/ELGX
Barchart Snapshot Opinion ~ http://barchart.com/snapopinion/stocks/ELGX
Barchart News Headlines ~ http://barchart.com/news/stocks/ELGX
Barchart Profile ~ http://barchart.com/profile//ELGX
Barchart Key Statistics ~ http://barchart.com/profile.php?sym=ELGX&view=key_statistics


OTC: American Bulls ~ http://www.americanbulls.com/StockPage.asp?CompanyTicker=ELGX&MarketTicker=OTC&TYP=S
NASDAQ: American Bulls ~ http://www.americanbulls.com/StockPage.asp?CompanyTicker=ELGX&MarketTicker=NASD&TYP=S
NYSE: American Bulls ~ http://www.americanbulls.com/StockPage.asp?CompanyTicker=ELGX&MarketTicker=NYSE&Typ=S


Marketwatch Profile ~ http://www.marketwatch.com/investing/stock/ELGX/profile
Marketwatch Analyst Estimates ~ http://www.marketwatch.com/investing/stock/ELGX/analystestimates
Marketwatch Historical Quotes ~ http://www.marketwatch.com/investing/stock/ELGX/historical
Marketwatch Financials ~ http://www.marketwatch.com/investing/stock/ELGX/financials
Marketwatch Overview ~ http://www.marketwatch.com/investing/stock/ELGX
Marketwatch SEC Filings ~ http://www.marketwatch.com/investing/stock/ELGX/secfilings
Marketwatch Picks ~ http://www.marketwatch.com/investing/stock/ELGX/picks
Marketwatch Hulbert ~ http://www.marketwatch.com/investing/stock/ELGX/hulbert
Marketwatch Insider Actions ~ http://www.marketwatch.com/investing/stock/ELGX/insideractions
Marketwatch Options ~ http://www.marketwatch.com/investing/stock/ELGX/options
Marketwatch Charts ~ http://www.marketwatch.com/investing/stock/ELGX/charts
Marketwatch News ~ http://bigcharts.marketwatch.com/news/symbolsearch/symbolnews.asp?news=markadv&symb=ELGX&sid=1795093&framed=False


The Lion ~ http://thelion.com/bin/aio_msg.cgi?cmd=search&msg=&si=1&tw=1&tt=1&rb=1&ih=1&fo=1&iv=1&yf=1&sa=1&fb=1&gg=1&symbol=ELGX


Search NYSE ~ http://www.nyse.com/about/listed/lcddata.html?ticker=ELGX


StockTA ~ http://www.stockta.com/cgi-bin/analysis.pl?symb=ELGX&num1=567&cobrand=&mode=stock


StockHouse ~ http://www.stockhouse.com/financialtools/sn_overview.aspx?qm_symbol=ELGX
StockHouse Delayed LII ~ http://www.stockhouse.com/financialtools/sn_level2.aspx?qm_page=46140&qm_symbol=ELGX


AlphaTrade ~ http://tools.alphatrade.com/index.php?t1=mc_quote_module&t2=mc_quote_module2&t3=historical&template=historical2html&sym=ELGX&client_id=2740&a_width=680&a_height=1000&language=english&showVol=1&chtype=8


Reuters ~ http://www.reuters.com/finance/stocks/companyOfficers?symbol=ELGX.PK&WTmodLOC=C4-Officers-5


StockWatch ~ http://www.stockwatch.com/Quote/Detail.aspx?symbol=ELGX®ion=U


Search NASDAQ ~ http://www.nasdaq.com/symbol/ELGX
NASDAQ Divy History ~ http://www.nasdaq.com/symbol/ELGX/dividend-history
NASDAQ Short Interest ~ http://www.nasdaq.com/symbol/ELGX/short-interest
NASDAQ Institutional Ownership ~ http://www.nasdaq.com/symbol/ELGX/institutional-holdings
NASDAQ FlashQuotes ~ http://www.nasdaq.com/aspx/flashquotes.aspx?symbol=ELGX&selected=ELGX
NASDAQ InfoQuotes ~ http://www.nasdaq.com/aspx/infoquotes.aspx?symbol=ELGX&selected=ELGX
NASDAQ After Hours Quote ~ http://www.nasdaq.com/symbol/ELGX/after-hours
NASDAQ Pre-Market Quote ~ http://www.nasdaq.com/symbol/ELGX/premarket
NASDAQ Historical Quote ~ http://www.nasdaq.com/symbol/ELGX/historical
NASDAQ Option Chain ~ http://www.nasdaq.com/symbol/ELGX/option-chain
NASDAQ Company Headlines ~ http://www.nasdaq.com/symbol/ELGX/news-headlines
NASDAQ Press Releases ~ http://www.nasdaq.com/symbol/ELGX/news-headlines
NASDAQ Sentiment ~ http://www.nasdaq.com/symbol/ELGX/sentiment
NASDAQ Analyst Summary ~ http://www.nasdaq.com/symbol/ELGX/analyst-research
NASDAQ Guru Analysis~ http://www.nasdaq.com/symbol/ELGX/guru-analysis
NASDAQ Stock Report ~ http://www.nasdaq.com/symbol/ELGX/stock-report
NASDAQ Competitors ~ http://www.nasdaq.com/symbol/ELGX/competitors
NASDAQ Stock Consultant ~ http://www.nasdaq.com/symbol/ELGX/stock-consultant
NASDAQ Stock Comparison ~ http://www.nasdaq.com/symbol/ELGX/stock-comparison
NASDAQ Call Transcripts ~ http://www.nasdaq.com/symbol/ELGX/call-transcripts
NASDAQ Annual Reports ~ http://www.nasdaq.com/aspx/annualreport.aspx?symbol=ELGX&selected=ELGX
NASDAQ Financials ~ http://www.nasdaq.com/symbol/ELGX/financials
NASDAQ Revenue & Earnings Per Share (EPS) ~ http://www.nasdaq.com/symbol/ELGX/revenue-eps
NASDAQ SEC Filings ~ http://www.nasdaq.com/symbol/ELGX/sec-filings
NASDAQ Ownership Summary ~ http://www.nasdaq.com/symbol/ELGX/ownership-summary
NASDAQ Institutional Ownership ~ http://www.nasdaq.com/symbol/ELGX/institutional-holdings
NASDAQ (SEC Form 4) ~
--------- All Trades ~ http://www.nasdaq.com/symbol/ELGX/insider-trades
--------- Buys ~ http://www.nasdaq.com/symbol/ELGX/insider-trades/buys
--------- Sells ~ http://www.nasdaq.com/symbol/ELGX/insider-trades/sells


The Motley Fool ~ http://caps.fool.com/Ticker/ELGX.aspx
The Motley Fool Earnings/Growth ~ http://caps.fool.com/Ticker/ELGX/EarningsGrowthRates.aspx?source=itxsittst0000001
The Motley Fool Ratios ~ http://caps.fool.com/Ticker/ELGX/Ratios.aspx?source=itxsittst0000001
The Motley Fool Stats ~ http://caps.fool.com/Ticker/ELGX/Stats.aspx?source=icasittab0000006
The Motley Fool Historical ~ http://caps.fool.com/Ticker/ELGX/Historical.aspx?source=icasittab0000004
The Motley Fool Scorecard ~ http://caps.fool.com/Ticker/ELGX/Scorecard.aspx?source=icasittab0000003
The Motley Fool Statements ~ http://caps.fool.com/Ticker/ELGX/Statements.aspx?source=icasittab0000009


MSN Money ~ http://investing.money.msn.com/investments/stock-ratings?symbol=ELGX


YCharts ~ http://ycharts.com/companies/ELGX
YCharts Performance ~ http://ycharts.com/companies/ELGX/performance
YCharts Dashboard ~ http://ycharts.com/companies/ELGX/dashboard


InsideStocks Opinion ~ http://www.insidestocks.com/texpert.asp?sym=ELGX&code=XDAILY
InsideStocks Profile ~ http://www.insidestocks.com/profile.asp?sym=ELGX&code=XDAILY
InsideStocks Quote ~ http://www.insidestocks.com/quote.asp?sym=ELGX&code=XDAILY
InsideStocks Projection ~ http://charts3.barchart.com/procal.asp?sym=ELGX


Zacks Quote ~ http://www.zacks.com/stock/quote/ELGX
Zacks Estimates ~ http://www.zacks.com/research/report.php?type=estimates&t=ELGX
Zacks Company Reports ~ http://www.zacks.com/research/report.php?type=report&t=ELGX


Knobias ~ http://knobias.10kwizard.com/files.php?sym=ELGX


StockScores ~ http://www.stockscores.com/quickreport.asp?ticker=ELGX


Trade-Ideas ~ http://www.trade-ideas.com/StockInfo/ELGX/HOT_TOPIC.html


Morningstar ~ http://performance.morningstar.com/stock/performance-return.action?region=USA&t=ELGX&culture=en-US
Morningstar Shareholders ~ http://investors.morningstar.com/ownership/shareholders-overview.html?t=ELGX®ion=USA&culture=en-us
Morningstar Transcripts~ http://www.morningstar.com/earnings/NoTranscript.aspx?t=ELGX®ion=USA
Morningstar Key Ratios ~ http://financials.morningstar.com/ratios/r.html?t=ELGX®ion=USA&culture=en-US
Morningstar Executive Compensation ~ http://insiders.morningstar.com/trading/executive-compensation.action?t=ELGX®ion=USA&culture=en-us
Morningstar Valuation ~ http://financials.morningstar.com/valuation/price-ratio.html?t=ELGX®ion=USA&culture=en-us


CCBN (Thompson Reuters) ~ http://ccbn.aol.com/company.asp?client=aol&ticker=ELGX


TradingMarkets ~ http://pr.tradingmarkets.com/?lid=leftPRbox&sym=ELGX


OTCBB ~ http://www.otcbb.com/asp/SiteSearch.asp?Criteria=ELGX&searcharea=e&image1.x=0&image1.y=0


Insidercow ~ http://www.insidercow.com/history/company.jsp?company=ELGX&B1=Search%21


Forbes News ~ http://search.forbes.com/search/find?tab=searchtabgeneraldark&MT=ELGX
Forbes Press Releases ~ http://search.forbes.com/search/find?&start=1&tab=searchtabgeneraldark&MT=ELGX&pub=businesswire,prnewswire&searchResults=pressRelease&tag=pr&premium=on
Forbes Web ~ http://search.forbes.com/search/web?MT=UNGS&start=1&max=10&searchResults=web&tag=web&sort=null


YouTube Symbol Search ~ http://www.youtube.com/results?search_query=ELGX


Buy-Ins ~ http://www.buyins.net/tools/symbol_stats.php?sym=ELGX


Quotemedia ~ http://www.quotemedia.com/results.php?qm_page=47556&qm_symbol=ELGX


Earnings Whispers ~ http://www.earningswhispers.com/stocks.asp?symbol=ELGX

Bloomberg Snapshot ~ http://investing.businessweek.com/research/stocks/snapshot/snapshot.asp?ticker=ELGX
Bloomberg People ~ http://investing.businessweek.com/research/stocks/people/people.asp?ticker=ELGX

Financial Times ~ http://markets.ft.com/Research/Markets/Tearsheets/Summary?s=ELGX

Investorpoint ~ http://www.investorpoint.com/ enter "ELGX" and click search.

Hotstocked ~ http://www.hotstocked.com/ enter "ELGX" and click search.

Raging Bull ~ http://ragingbull.quote.com/mboard/boards.cgi?board=ELGX

Hoovers ~ http://www.hoovers.com/search/company-search-results/100003765-1.html?type=company&term=ELGX

DD Machine ~ http://www.ddmachine.com/default.asp?m=stocktool_frame.asp?symbol=ELGX

SEC Form 4 ~ http://www.secform4.com/insider/showhistory.php?cik=ELGX

OTCBB Pulse ~ http://www.otcbbpulse.com/cgi-bin/pulsequote.cgi?symbol=ELGX

Failures To Deliver ~ http://failurestodeliver.com/default2.aspx enter "ELGX" and click search.

http://www.coordinatedlegal.com/SecretaryOfState.html

http://regsho.finra.org/regsho-Index.html

http://www.shortsqueeze.com/?symbol=ELGX&submit=Short+Quote%99



DTCC (PENSON/TDA) Check - (otc and pinks) - Note ~ I did not check for this chart blast. However, I try and help you to do so with the following links.
IHUB DTCC BOARD SEARCH #1 http://investorshub.advfn.com/boards/msgsearchbyboard.aspx?boardID=18682&srchyr=2011&SearchStr=ELGX
IHUB DTCC BOARD SEARCH #2: http://investorshub.advfn.com/boards/msgsearchbyboard.aspx?boardID=14482&srchyr=2011&SearchStr=ELGX
Check those searches for recent ELGX mentions. If ELGX is showing up on older posts and not on new posts found in link below, The DTCC issues may have been addressed and fixed. Always call the broker if your security turns up on any DTCC/PENSON list.
http://investorshub.advfn.com/boards/msgsearchbyboard.aspx?boardID=18682&srchyr=2011&SearchStr=Complete+list
For a complete list see the pinned threads at the top here ---> http://tinyurl.com/TWO-OLD-FARTS



MACDlinks

~ Thursday! $ELGX ~ Q1 Earnings posted, pending or coming soon! In Charts and Links Below!

~ $ELGX ~ Earnings expected on Thursday *
Want more like this? Search Keyword: MACMONEY >>> http://tinyurl.com/MACMONEY <<<
One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.








http://stockcharts.com/h-sc/ui?s=ELGX&p=D&b=3&g=0&id=p88783918276&a=237480049




http://stockcharts.com/h-sc/ui?s=ELGX&p=W&b=3&g=0&id=p54550695994



~ Google Finance: http://www.google.com/finance?q=ELGX
~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=ELGX#
~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=ELGX+Key+Statistics
~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=ELGX
Finviz: http://finviz.com/quote.ashx?t=ELGX
~ BusyStock: http://busystock.com/i.php?s=ELGX&v=2


<<<<<< http://www.earningswhispers.com/stocks.asp?symbol=ELGX >>>>>>



http://investorshub.advfn.com/boards/post_prvt.aspx?user=251916

*If the earnings date is in error please ignore error. I do my best.

Reported: $12
Endologix misses by $0.01, reports revs in-line; guides FY12 EPS below consensus, revs in-line (ELGX) : Reports Q4 (Dec) loss of $0.06 per share, $0.01 worse than the Capital IQ Consensus Estimate of ($0.05); revenues rose 21.9% year/year to $23.4 mln vs the $23.51 mln consensus. Co issues mixed guidance for FY12, sees EPS of ($0.12)-(0.18) vs. ($0.05) Capital IQ Consensus Estimate; sees FY12 revs of $102-107 mln vs. $106.42 mln Capital IQ Consensus Estimate. Co expects quarterly progress towards profitability over the course of the year. Guidance takes into account the planned growth of the direct sales force in Europe, and research & development and clinical/regulatory initiatives, particularly for the Nellix and Ventana devices. Not included in this loss per share guidance are potential adverse litigation outcomes, fair value adjustments associated with the Nellix acquisition, or the effect of other possible business development transactions. The Company expects to be cash flow positive in the second half of 2012 and believes that it has adequate cash resources to fund its operations and growth strategies.

~ Monday! $ELGX ~ Earnings posted, pending or coming soon! In Charts and Links Below!

~ $ELGX ~ Earnings expected on Monday *
Want more like this? Search Keyword: MACMONEY >>> http://tinyurl.com/MACMONEY <<<
One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.








http://stockcharts.com/h-sc/ui?s=ELGX&p=D&b=3&g=0&id=p88783918276&a=237480049




http://stockcharts.com/h-sc/ui?s=ELGX&p=W&b=3&g=0&id=p54550695994



~ Google Finance: http://www.google.com/finance?q=ELGX
~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=ELGX#
~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=ELGX+Key+Statistics
~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=ELGX
Finviz: http://finviz.com/quote.ashx?t=ELGX
~ BusyStock: http://busystock.com/i.php?s=ELGX&v=2


<<<<<< http://www.earningswhispers.com/stocks.asp?symbol=ELGX >>>>>>



http://investorshub.advfn.com/boards/post_prvt.aspx?user=251916

*If the earnings date is in error please ignore error. I do my best.

test